Product Name:
DYRK2-pY382
Product Number:
ab-pk598
Target Full Name: Dual specificity tyrosine-phosphorylation-regulated kinase 2
Target Alias: Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2; DYRK2; FLJ21217; FLJ21365
Product Type Specific: DYRK2 protein kinase phosphosite-specific antibody
Antibody Code: PK598
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y382
Protein UniProt: Q92630
Protein SigNET: DYRK2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human DYRK2 sequence peptide
Antibody Immunogen Sequence: VYT(pY)IQS(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues V379 to S385; in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y382 phosphorylation is predicted to be stimulatory for phosphotransferase activity. This is one of the major in vivo phosphorylation sites in DYRK2 (≥1659 reports from high throughput mass spectrometry studies recorded in PhosphoSitePlus).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.3 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Frog | Zebra fish | Fruit fly | Sea urchin | Budding yeast.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 60-70 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in HeLa, A431 and MCF7 cells.
Related Product 1: DYRK2-ANT pan-specific antibody (Cat. No.: AB-NK266-1)
Related Product 2: DYRKSubtide kinase substrate peptide (Cat. No.: PE-01BHD95)
Related Product 3: DYRK1A Y321 phosphorylation antibody (Cat. No.: AB-PK597)
Related Product 4: DYRK2 expression antibody (Cat. No.: AB-NK266-1)
Scientific Background: DYRK2 is a protein-serine/threonine kinase of the CMGC group and DYRK family. It is a dual-specificity protein kinase that regulates cell cycle progression, cell proliferation, apoptosis, cytoskeletal organization, and neurite outgrowth. DYRK2 functions downstream of ATM and directly phosphorylates p53/T53 at the Ser-46 to promotion of apoptosis in the presence of DNA damage. DYRK2 regulates protein homeostasis by phosphorylating the 19S proteasome subunit Rpt3, thereby promoting proteasome activity and reducing proteotoxic stress. Other substrates include NFAT4, and katanin p60. In addition, DYRK2 functions in ubiquitin-dependent proteasomal protein degradation, specifically promoting the degradation of the oncoproteins in the Myc and Jun families. DYRK2 appears to function as a tumour suppressor protein (TSP). It acts as a kinase-independent scaffold for the EDVP (EDD-DDB1-VprBP) E3 ubiquitin ligase complex, facilitating the degradation of proteins involved in cell cycle progression and centrosome organization. Abnormal expression of DYRK2 have been associated with various forms of human cancer. In breast cancer cells, DYRK2 negatively regulates the stability of Snail, a transcription factor that regulates the epithelial-mesenchymal transistion (EMT). Knock-down of DYRK2 expression in breast cancer cells promotes EMT and tumour invasion both in vitro and in vivo. In addition, tumours with low expression of DYRK2 were correlated with a significantly lower patient survival and higher metastasis rate than tumours with high DYRK2 expression. Therefore, the DYRK2 protein appears to be a critical suppressor of cancer invasion and metastasis. It is overexpressed in certain adenocarcinoma tissues. Similarly, the 5-year survival rates of pulmonary adenocarcinoma patients was significant higher for those with DYRK2-positive tumours (89. 2%) than those with DYRK2-negative tumours (66. 3%), indicating a critical role for DYRK2 as a tumour suppressor in this cancer type as well. This description may include information annotated by UniProt and/or Google AI.